Axitinib inhibits oral mucosal melanoma growth through modulating vasculogenic mimicry in a patient-derived xenograft model

doi:10.19438/j.cjoms.2018.04.002

Abstract

Abstract: PURPOSE:To investigate the potential application of axitinib in treatment of oral mucosal melanoma (OMM). METHODS: After successful establishment of oral mucosal melanoma-bearing patient derived xenografts (PDX) model, 16 nude mice were randomly divided into control and experimental group. After oral administration of axitinib or sodium carboxymethylcellulose for 28 days, the tumors were assessed for histological and molecular features by immunochemical assay as well as growth status at least twice a week using vernier caliper. Vasculogenic mimicry was evaluated by immunochemistry and periodic acid schiff reaction (PAS) histochemical double-staining. SPSS 23.0 software package was used for statistical analysis. RESULTS: Compared to the control group, tumor volume, amount of vasculogenic mimicry and CD34-positive vessels in the axitinib group were significantly decreased after oral administration (P<0.05); meanwhile, the protein level of EphA2 and MMP-2 was significantly decreased in the axitinib group, and the expression of HIF-1a was significantly higher than the control group(P<0.05). CONCLUSIONS: Axitinib could be applied in target treatment of OMM.

Key words: Oral mucosal melanoma, Patient derived xenografts, Vasculogenic mimicry, Axitinib

CLC Number:

R739.85

HONG Duo, GU Zi-yue, LI Jiang, ZHANG Zhi-yuan. Axitinib inhibits oral mucosal melanoma growth through modulating vasculogenic mimicry in a patient-derived xenograft model[J]. China Journal of Oral and Maxillofacial Surgery, 2018, 16(4): 296-301.

References

[1] Yang X, Ren GX, Zhang CP, et al.Neck dissection and post-operative chemotherapy with dimethyl triazeno imidazole carboxamide and cisplatin protocol are useful for oral mucosal melanoma[J]. BMC Cancer, 2010, 10: 623.
[2] Gray-Schopfer V, Wellbrock C, Marais R.Melanoma biology and new targeted therapy[J]. Nature, 2007, 445(7130): 851-857.
[3] Tripp MK, Watson M, Balk SJ, et al.State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now[J]. CA Cancer J Clin, 2016, 66(6): 460-480.
[4] 中华口腔医学会口腔颌面外科专业委员会肿瘤学组. 口腔颌面部恶性肿瘤治疗指南[J]. 中国实用口腔科杂志, 2010, 3(7): 395-403.
[5] 郭伟, 任国欣, 王新, 等. 口腔颌面-头颈恶性黑色素瘤综合治疗探索及进展[C]. 杭州: 国际暨全国头颈肿瘤学术大会, 2011.
[6] Kee D, Mcarthur G.Targeted therapies for cutaneous melanoma[J]. Hematol Oncol Clin North Am, 2014, 28(3): 491-505.
[7] Read J.Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment[J]. Australas J Dermatol, 2013, 54(3): 163-172.
[8] Quintáscardama A, Lazar AJ, Woodman SE, et al.Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib[J]. Nat Clin Pract Oncol, 2008, 5(12): 737-740.
[9] Lyu J, Wu Y, Li C, et al.Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases[J]. J Oral Pathol Med, 2016, 45(4): 295-301.
[10] Satzger I, Schaefer T, Kuettler U, et al.Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas[J]. Br J Cancer, 2008, 99(12): 2065-2069.
[11] Zhang S, Zhang D, Sun B.Vasculogenic mimicry: current status and future prospects[J]. Cancer Lett, 2007, 254(2): 157-164.
[12] Song H, Jing G, Wang L, et al.Periodic acid-Schiff-positive loops and networks as a prognostic factor in oral mucosal melanoma[J]. Melanoma Res, 2016, 26(2): 145-152.
[13] Zhang S, Li M, Gu Y, et al.Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma[J]. J Exp Clin Cancer Res, 2008, 27: 60.
[14] 张月英, 王兆朋, 王朝霞, 等. 索拉非尼抑制人肝癌裸鼠皮下移植瘤血管生成拟态作用研究[J]. 国际肿瘤学杂志, 2015, 42(10): 721-725.
[15] Fruehauf J, Lutzky J, Mcdermott D, et al.Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma[J]. Clin Cancer Res, 2011, 17(23): 7462-7469.
[16] Hu-Lowe DD, Zou HY, Grazzini ML, et al.Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3[J]. Clin Cancer Res, 2008, 14(22): 7272-7283.
[17] Rixe O, Bukowski RM, Michaelson MD, et al.Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study[J]. Lancet Oncol, 2007, 8(11): 975-984.
[18] Schiller JH, Larson T, Ou SH, et al.Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study[J]. J Clin Oncol, 2009, 27(23): 3836-3841.
[19] Cohen EE, Rosen LS, Vokes EE, et al.Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study[J]. J Clin Oncol, 2008, 26(29): 4708-4713.
[20] Chi Z, Li S, Sheng X, et al.Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases[J]. BMC Cancer, 2011, 11: 85.
[21] Shoo BA, Kashanisabet M.Melanoma arising in African-, Asian-, Latino- and Native-American populations[J]. Semin Cutan Med Surg, 2009, 28(2): 96-102.
[22] Tentler JJ, Tan AC, Weekes CD, et al.Patient-derived tumour xenografts as models for oncology drug development[J]. Nat Rev Clin Oncol, 2012, 9(6): 338-350.
[23] Folberg R, Hendrix MJ, Maniotis AJ.Vasculogenic mimicry and tumor angiogenesis[J]. Am J Pathol, 2000, 156(2): 361-381.
[24] Sun B, Zhang S, Zhao X, et al.Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas[J]. Int J Oncol, 2004, 25(6): 1609-1614.
[25] Maniotis AJ, Folberg R, Hess A, et al.Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry[J]. Am J Pathol, 1999, 155(3): 739-752.
[26] Hulowe DD, Zou HY, Grazzini ML, et al.Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3[J]. Clin Cancer Res, 2008, 14(22): 7272-7283.
[27] Rugo HS, Herbst RS, Liu G, et al.Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results[J]. J Clin Oncol, 2005, 23(24): 5474-5483.